Market revenue in 2023 | USD 538.0 million |
Market revenue in 2030 | USD 789.8 million |
Growth rate | 5.6% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Research & Manufacturing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Research & Manufacturing |
Key market players worldwide | GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Roche Holding AG, Qiagen NV, Becton Dickinson & Co, Siemens Healthineers AG ADR, Thermo Fisher Scientific Inc, Hologic Inc, Koninklijke Philips NV, Illumina Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to blood cancer diagnostics market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 65.71% in 2023. Horizon Databook has segmented the Germany blood cancer diagnostics market based on hospitals, outpatient facilities, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
The German Cancer Society (DKG) estimates that there are around 54,000 new cases of blood cancer diagnosed annually in Germany, with leukemia accounting for around 35% of these cases. In 2020, around 13,570 people in Germany were diagnosed with leukemia, a significant percentage of which, 4%, affected individuals under the age of 15.
The risk of developing leukemia tends to decrease with increasing age among children and young adults, indicating a notable pattern in the disease's incidence. The German government launched the "National Decade Against Cancer" program in 2020, which included initiatives to improve early detection and diagnosis of cancer, including blood cancers.
Germany's comprehensive healthcare system is renowned for its ability to detect blood cancers at an early stage, enabling prompt treatment initiation and, subsequently, better outcomes. The country's extensive range of treatment options allows healthcare professionals to develop personalized treatment plans that cater to each patient's unique needs.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany blood cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into Germany blood cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account